

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for BM3300

Apolipoprotein A I (APOA1) Mouse Monoclonal Antibody [Clone ID: 1402]

Product data:

Product Type:	Primary Antibodies
Clone Name:	1402
Applications:	ELISA, R
Recommended Dilution:	Competitive RIA or EIA.
Reactivity:	Human
Host:	Mouse
lsotype:	lgG1
Clonality:	Monoclonal
Immunogen:	Purified human plasma Apo A-I
Specificity:	Detects Apolipoprotein AI. No cross reactivity with APO A-II or Apo B.
Formulation:	0.015 M Potassium phosphate buffer, 0.15 M NaCl, pH 7.2 containing 0.09% sodium azide as preservative State: Purified State: Liquid purified Ig fraction
Concentration:	lot specific
Purification:	DEAE Chromatography
Conjugation:	Unconjugated
Storage:	Store the antibody at 2-8°C for one month or at -20°C for longer. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Gene Name:	apolipoprotein A1
Database Link:	Entrez Gene 335 Human P02647



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2024 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

	Apolipoprotein A I (APOA1) Mouse Monoclonal Antibody [Clone ID: 1402] – BM3300
Background:	Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the
	The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.
Synonyms:	APOA1, ApoA-I, Apo-AI, ApoAI

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2024 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US